After cutting coverage because of cost, the state health plan could return GLP-1 weight loss drugs to the plan ...

Omada Health is joining forces with CVS Health's Caremark as part of the pharmacy benefit manager's weight management program ...

Research shows weight loss surgery can help reduce the risk of severe liver problems for some patients with MASH.

A groundbreaking study from the University of British Columbia has revealed a potentially disturbing side effect for those ...

Compounded versions could make up as much as 40% of the semaglutide market, said Novo Nordisk CEO Lars Fruergaard Jorgensen ...

The benefits of naltrexone/bupropion (Mysimba) continue to outweigh its risks, despite ongoing uncertainty about long-term ...

Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish ...

Losing weight is a common New Year’s resolution, and many people are now turning to advanced weight-loss medications like ...

Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an “important” weight loss treatment.

Are we truly on the brink of a cure for obesity? Or could neglecting the root causes risk worsening the very problems we seek ...

There’s no question about the popularity of GLP-1 weight loss drugs like Ozempic and Wegovy, but some doctors are worried the ...

Novo Nordisk has licensed an oral obesity drug that works via an uncommon mechanism and may help patients maintain their ...